Search Results

The UltraCon™ Ultrafiltrator is indicated for use as an ultrafiltrator for the selective removal of undesireable plasma water and small dissolved solutes from blood plasma proteins and formed cellular elements, as may be present in cases of acute hemodilution such as following cardiopulmonary bypass.

The Ultracon™ Ultrafiltrator is constructed of semipermeable hollow fibers, which divide the device into two compartments. An inner pathway for diluted blood perfusate is defined by the inlet and outlet connectors and flow dispersion headers, which are connected through the inner lumen of semipermeable hollow fiber membranes. Surrounding the hollow fibers is an enclosed, vented compartment for the collection of ultrafiltrate waste water.

When dilute blood or a blood component is allowed to pass through the perfusate pathway, the device acts as an ultrafilter, removing a percentage of the plasma water and small solutes from the perfusate. When perfusate fluid passes through the inner diameter of the hollow fibers, water and small dissolved solutes can pass through the semipermeable membrane walls into the annular ultrafiltrate compartment, to then be discarded. This results in the concentration of formed elements and proteins as they pass along the perfusate pathway.

The UltraCon™ Ultrafiltrator is built with dry cellulose diacetate membranes, a unique material which has been shown to have a high level of biocompatibility. The absence of any bore fluid provides the convenience of using the device without the need for rinsing. Each device is supplied in a sealed plastic and foil package, to maintain a sterile, non-pyrogenic perfusate pathway.

Although constructed of highly permeable membrane material, the low total membrane surface area of the UltraCon™ Ultrafiltrator inherently limits the maximum rate of water removal. Neither an ultrafiltration rate monitor nor a controller is necessary. Average ultrafiltration rate will vary directly according to perfusate flow rate, transmembrane pressure, or temperature, and inversely according to its protein concentration and hematocrit.

The provided document is a 510(k) Summary for the UltraCon™ Ultrafiltrator, dated February 24, 1998. It primarily focuses on demonstrating substantial equivalence to predicate devices, rather than presenting a detailed study with specific acceptance criteria and performance data in the format requested.

Therefore, much of the requested information, such as detailed acceptance criteria, specific performance metrics from a study against those criteria, sample sizes for test and training sets, expert qualifications, adjudication methods, and MRMC study details, is not present in the provided document.

However, based on the information available, I can extract and infer the following:

1. A table of acceptance criteria and the reported device performance

The document does not explicitly present a table of acceptance criteria linked to a study's performance results. Instead, it lists "UltraCon™ Ultrafiltrator Specifications" which serve as design specifications and implicitly, as targets for acceptable performance. The comparison to predicate devices also implies that performance similar to these predicates would be acceptable.

Ask a specific question about this device